[Asia Economy Reporter Minwoo Lee] PharmAbcine announced on the 21st that it has obtained a patent for 'New EGFRvIII Antibody and Compositions Containing the Same.'
The company stated, "This patent relates to an antibody that does not cross-react with EGFR but specifically binds to EGFRvIII, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumors containing the antibody as an active ingredient." They explained, "EGFRvIII is a target expressed only in tumors and not in normal cells, and it can be utilized in the development of therapeutics such as antibody-drug conjugates (ADC), CAR-T, CAR-NK, CAR-Macrophage, and bispecific antibodies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
